Celgene's Revlimid filing accepted by EMA, as solid trends reported
This article was originally published in Scrip
Executive Summary
Celgene's apparent strategy in 2011 is to consolidate the strength of its Revlimid (lenalidomide), its leading anticancer drug, by geographical in-fill of niches in sales and regulatory approval, and moving outwards from that base into related areas of therapeutic need.